1 Result: Mesoblast
Mesoblast Faces Regulatory Setback; Nikola's Earnings: A Preview
August 04th, 2023
Mesoblast Limited (Nasdaq: MESO) has announced the receipt of a comprehensive response from the US Food and Drug Administration (FDA) regarding its Biologics License Application (BLA) resubmission for remestemcel-L. The FDA's response stipulates the . Read more
Load More Content
Want To Find Some News?
News By Industries
Recent Post
-
Earnings Countdown: Lockheed Martin, Stryker, and PACCAR Gear Up
January 26th, 2025Earnings Spotlight: SoFi Technologies, Sanmina, and Nucor Set to Report
January 26th, 2025Global Flag Football League Plans To Host Pro Flag Football Tournament in Las Vegas
January 23rd, 2025Earnings On Deck: Netflix, United Airlines, and Agilysys Gear Up
January 19th, 2025
Member Login